NEWRON PHARMACEUT. EO-20 Cash Flow Quality Index

Latest as of December 2024: -1.11x

NEWRON PHARMACEUT. EO-20 cash flow quality index. NEWRON PHARMACEUT. EO-20 (NP5) has a Cash Flow Quality Index of -1.11x as of December 2024. Operating cash flow of €-17.61 Million is below net income of €15.84 Million, suggesting accrual-heavy earnings not yet converted to cash. See NEWRON PHARMACEUT. EO-20 leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.

Cash Flow Quality Index

-1.11x

Operating CF / Net Income

Operating Cash Flow

€-17.61 Million

EUR

Net Income

€15.84 Million

EUR

Data as of

Dec 2024

Most recent filing

Cash Flow Quality Index of NEWRON PHARMACEUT. EO-20 (2024–2024)

Cash flow quality index of NEWRON PHARMACEUT. EO-20 from 2024 to 2024. Historical Cash Flow Quality Index for NEWRON PHARMACEUT. EO-20 across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore NP5 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

NEWRON PHARMACEUT. EO-20 Cash Flow Quality Index by Year (2024–2024)

NEWRON PHARMACEUT. EO-20 cash flow quality index by year from 2024 to 2024. Year-by-year earnings quality comparison for NEWRON PHARMACEUT. EO-20. For the full cash flow conversion analysis, see NEWRON PHARMACEUT. EO-20 cash conversion from operations.

Year	Quality Index	Operating CF (EUR)	Net Income	YoY Change
2024	-1.11x	€-17.61 Million	€15.84 Million	—

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.